This clinical trial is focused on studying the treatment of acute vulvovaginal candidiasis, a common yeast infection that affects the vaginal area, causing symptoms like itching, burning, and irritation. The study will compare the effectiveness and safety of a new medication called Albaconazole (also known by its code name UR-9825) with another medication, Fluconazole, and a placebo. Both Albaconazole and Fluconazole are taken as hard capsules by mouth.

The purpose of the study is to determine how well different single doses of Albaconazole work in treating the infection compared to a placebo. Participants will be randomly assigned to receive either Albaconazole, Fluconazole, or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment until the study is completed. This helps ensure that the results are not biased.

Throughout the study, participants will have regular check-ups to monitor their health and the effectiveness of the treatment. The main goal is to see if the symptoms of the infection are completely resolved by the end of the study. The trial will help researchers understand the best dose of Albaconazole for treating acute vulvovaginal candidiasis and compare its effectiveness to Fluconazole and a placebo.